Cited by 160Dermatology and Skin DiseasesContact Dermatitis and AllergiesPain Mechanisms and Treatments

Peripheral itch sensitization in atopic dermatitis

Open access
Tominaga, Mitsutoshi, Takamori, Kenji·2022·Allergology International

Abstract

Atopic dermatitis is a skin disorder caused by skin dryness and barrier dysfunction, resulting in skin inflammation and chronic itch (or pruritus). The pathogenesis of atopic dermatitis is thought to be initiated by a lowering of the itch threshold due to dry skin. This lowering of the itch threshold is at least partially due to the increase in intraepidermal nerve fibers and sensitization of sensory nerves by interleukin (IL)-33 produced and secreted by keratinocytes. Such skin is easily prone to itch due to mechanical stimuli, such as rubbing of clothing and chemical stimuli from itch mediators. In patients with atopic dermatitis, once itch occurs, further itch is induced by scratching, and the associated scratching breaks down the skin barrier. Disruption of the skin barrier allows entry into the epidermis of external foreign substances, such as allergens derived from house dust mites, leading to an increased induction of type 2 inflammatory responses. As a result, type 2 cytokines IL-4, IL-13, and IL-31 are mainly secreted by Th2 cells, and their action on sensory nerve fibers causes further itch sensitization. These sequences of events are thought to occur simultaneously in patients with atopic dermatitis, leading to a vicious itch-scratch cycle. This vicious cycle becomes a negative spiral that leads to disease burden. Therefore, controlling itch is essential for the treatment of atopic dermatitis. In this review, we summarize and discuss advances in the mechanisms of peripheral itch sensitization in atopic dermatitis, focusing on skin barrier-neuro-immune triadic connectivity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.alit.2022.04.003

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The type 2 cytokine milieu downregulates antimicrobial peptides, facilitating microbial colonization, particularly by Staphylococcus aureus, which amplifies inflammation through superantigen production and Th2 polarization.

    “Furthermore, this cytokine milieu downregulates antimicrobial peptides, facilitating microbial colonization, particularly by Staphylococcus aureus, which amplifies inflammation through superantigen production and Th2 polarization.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [9]

    In “Itch mediators other than histamine” (page unavailable), the paper says that β-defensins, a class of antimicrobial peptides, are highly expressed in the epidermis of patients with atopic dermatitis—not that they are downregulated. It does not describe the claimed Staphylococcus aureus colonization, superantigen production, or Th2-polarization chain. (LLM, conf=0.78)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Epithelial-derived alarmins such as TSLP, IL-25, and IL-33 activate dendritic cells and group 2 innate lymphoid cells (ILC2s), promoting Th2 differentiation and perpetuating cytokine release.

    “In parallel, epithelial-derived alarmins such as TSLP, IL-25, and IL-33 activate dendritic cells and group 2 innate lymphoid cells (ILC2s), promoting Th2 differentiation and perpetuating cytokine release [7,8,9].”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [9]

    The “Normal skin” section (page not available in our copy) says that keratinocyte-derived IL-33 and TSLP activate ILC2, which secrete IL-13 and IL-5 and induce type 2 inflammation. It does not establish the claimed role of IL-25, activation of dendritic cells by these alarmins, or the resulting Th2 differentiation. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Chronic atopic dermatitis is thought to be sustained by skin-resident memory T cells, which rapidly produce type 2 cytokines and contribute to recurrent inflammation.

    “Chronic disease is thought to be sustained by skin-resident memory T cells, which rapidly produce type 2 cytokines and contribute to recurrent inflammation.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [9]

    The “Normal skin” passage says Th2 cells secrete type 2 cytokines in acute atopic dermatitis lesions, and “Chronic lesion of atopic dermatitis” describes a continuing inflammatory response. Neither passage identifies those cells as skin-resident memory T cells or says they rapidly produce cytokines to drive recurrence. Page numbers are unavailable in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Eosinophils, activated downstream of IL-5 and type 2 cytokines, contribute to tissue remodeling and inflammation.

    “Eosinophils, activated downstream of IL-5 and type 2 cytokines, further contribute to tissue remodeling and inflammation.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [9]

    The IL-33 section (page unavailable) says IL-33 activates eosinophils involved in allergic inflammation. The Normal skin section (page unavailable) says ILC2 secrete IL-5 and IL-13 to induce type 2 inflammation. Neither passage says IL-5 activates eosinophils or that eosinophils contribute to tissue remodeling. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • IL-4, IL-13, and IL-31, produced upon antigen re-exposure, maintain inflammation even in clinically normal skin.

    “IL-4, IL-13, and IL-31, produced upon antigen re-exposure, maintain inflammation even in clinically normal skin.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [9]

    The “Normal skin” section says allergen antigens can trigger a type 2 inflammatory response, but places IL-4, IL-13, and IL-31 secretion in acute atopic dermatitis lesions. It does not say these three cytokines are produced upon antigen re-exposure or maintain inflammation in clinically normal skin; it describes the immune response in normal skin as normal. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. St€ ander S, Grundmann SA. Chronic pruritus. G Ital Dermatol Venereol 2012;147:161e9.
  2. Wilzopolski J, Kietzmann M, Mishra SK, Stark H, Baumer W, Rossbach K. TRPV1 and TRPA1 channels are both involved downstream of histamine- induced itch. Biomolecules 2021;11:1166.
  3. Tseng PY, Hoon MA. Specific beta-defensins simulate pruritus through acti- vation of sensory neurons. J Investig Dermatol 2022;142:594e602.

Cited by

Sorted by citations

Authors
Tominaga, M., & Takamori, K.
Affiliations
Juntendo University (JP)
Corresponding author
Tominaga, Mitsutoshi
Venue
Allergology International
Publisher
Elsevier BV
Published
2022-07
Volume
71
Issue
3
Pages
265-277
ISSN
1323-8930 (ISSN-L)
OpenAlex
W4281485602
Cited by
160
References
137
Citations by year
2026: 38 · 2025: 56 · 2024: 32 · 2023: 28 · 2022: 6
FWCI
5.43
Type
journal article
Language
en
Open access
Locations
  • Allergology International (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cosmetology Research Foundation
  • Japan Society for the Promotion of Science (22H02956, 23K20320, S1311011, 18K07396, 20H03568, 23K24217)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
Keywords
atopic dermatitis, pruritus, itch-scratch cycle, skin barrier dysfunction, IL-33, keratinocytes, intraepidermal nerve fibers, type 2 cytokines, IL-4, IL-13, IL-31, Th2 cells, house dust mite allergens, neuroimmune interactions
MeSH terms
Allergens, Dermatitis, Atopic, Epidermis, Humans, Pruritus, Skin, Cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review